Picture of Yield10 Bioscience logo

YTENQ — Yield10 Bioscience News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro Cap

Yield10 Bioscience Inc expected to post a loss of 54 cents a share - Earnings Preview

* Yield10 Bioscience Inc  YTEN.OQ   YTEN.O  is expected
to show a
fall in quarterly revenue when it reports  results on August 8
(estimated). 
    * The Woburn Massachusetts-based  company is expected to
report  a
67.6% decrease in revenue to $33.33 thousand from $103 thousand
a year ago, according to the mean estimate from 3 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Yield10 Bioscience
Inc is
for a loss of 54 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Yield10
Bioscience Inc is $12​, above​ its last closing price of $1.95.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.63       -0.63      -0.76     Missed  -20
 Dec. 31 2023  -0.69       -0.60      -0.67     Missed  -10.7
 Sep. 30 2022  -0.65       -0.65      -0.71     Missed  -9.2​
 Jun. 30 2022  -0.69       -0.69      -0.70     Missed  -1.4
 ​​Mar.        -0.65       -0.65      -0.68     Missed  -4.2
 31 2022                                                
 Dec. 31 2021  -0.64       -0.63      -0.61     Beat    3.9​
 Sep. 30 2021  -0.65       -0.65      -0.49     Beat    24.6
 Jun. 30 2021  -0.54       -0.54      -0.64     Missed  -18.5
 This summary was machine generated August 4 at 11:15 GMT.  All
figures in US dollars  unless otherwise stated

Recent news on Yield10 Bioscience

See all news